Update on the pharmacotherapy for myelodysplastic syndromes.
about
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
P2860
Update on the pharmacotherapy for myelodysplastic syndromes.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Update on the pharmacotherapy for myelodysplastic syndromes.
@en
type
label
Update on the pharmacotherapy for myelodysplastic syndromes.
@en
prefLabel
Update on the pharmacotherapy for myelodysplastic syndromes.
@en
P2860
P1476
Update on the pharmacotherapy for myelodysplastic syndromes
@en
P2093
Rami S Komrokji
Vu H Duong
P2860
P304
P356
10.1517/14656566.2014.937705
P407
P50
P577
2014-07-31T00:00:00Z